Company intelligence / Profile preview

SpectroCor

Ownership: Private
Development stage: Clinical

Overview

SpectroCor has developed and commercialized a real-time, optical sensor-based device that monitors myocardial oxygenation during open-heart surgery. The technology is designed to help surgeons optimize myocardial protection, reduce complications such as ischemia-reperfusion injury, and improve patient outcomes by providing actionable data throughout the procedure. Clinical results indicate improved quality control and workflow optimization in cardiac operations[1][2][4].

Therapeutic areas: Cardiovascular
Modalities: DeviceOptical sensor-based monitoring system
Industry: Physiological Monitoring

Drug pipeline

1 asset

SpectroCor

Clinical

Indications: Myocardial ischemia, Cardiac surgery complications

Beyond the preview

Go deeper on SpectroCor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpectroCor.

Explore the full profile